Medical Device News Magazine

Vivalink Releases Biometrics Data Platform 2.0, Increasing Remote Patient Monitoring Patient Adherence

New updates address common industry challenges for RPM patient adherence in clinical trials and healthcare

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Vivalink, a leading provider of digital healthcare solutions, has released an updated version of its Biometrics Data Platform with new features aimed at increasing patient adherence in Remote Patient Monitoring (RPM).

Vivalink’s Biometrics Data Platform accelerates the implementation and time-to-market of remote patient monitoring for healthcare and clinical trials by combining a turn-key end-to-end solution consisting of a suite of wearable sensors, edge-to-cloud integration, and advanced data  management and analytics both in real-time and retrospectively. The software platform is designed for flexible interoperability with mobile and web enabled clinical applications, electronic health record (EHR) systems and clinical trial management systems (CTMS).

While the adoption of RPM has accelerated with the pandemic and is expected to grow exponentially, patient adherence remains a top challenge. In a Decentralized Clinical Trial (DCT) survey by Vivalink, 69 percent of respondents indicated ‘patient adherence’ as the top concern.

To address this concern, the new Biometrics Data Platform updates include:

  • Data Integrity Assurance – notification of interruptions in data capture
  • New Adhesives Options – designed for sensitive skin and facilitates extended wear times
  • Sensor Status Indicators – detects when sensors are not connected or have become disconnected
  • Central Operational Console – systems management view of distributed patient sensors and data capture status across multiple locations to ensure proper adherence
  • Data Management Portal – A multi-functional web portal for patient/participant management, vital data visualization, analysis, and notifications based on advanced algorithms

Vivalink takes a “patient centric” approach to its RPM solution, which includes making its devices as easy to use and comfortable as possible for the patient. For example, its medical grade multi-vital cardiac patch is among the world’s smallest and lightest, weighing just 7.5 grams, increasing comfort while reducing disruption to daily routines.

“As a technology solution provider, we strive for the most advanced and effective solutions for remote patient monitoring,” said Jiang Li, CEO of Vivalink. “Patient adherence is a major bottleneck for the wider adoption of RPM. Today’s release of these features focusing on improving patient adherence shows our firm commitment to the patient-centric approach of our solution.

”More than 150 digital healthcare solution partners and commercial customers in 41 countries are delivering a wide range of medical applications using Vivalink’s Biometrics Data Platform. Vivalink’s solution is the basis of clinical research studies at leading institutions, including a 3,000 patient atrial fibrillation study at UCSF and a study of the effects of stress and teenage depression at Stanford University. Most recently, the platform has been adopted by health technology companies developing AI solutions, algorithm development and validation. The platform meets high levels of global compliance, including HIPAA, GDPR, FDA 21 CFR Part 11, ISO 13485, IEC 62304, ISO 14971, ISO 10993, and ISO 27001.

For more information, visit www.vivalink.com.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”